» Articles » PMID: 27098091

Pristimerin Attenuates Ovalbumin-induced Allergic Airway Inflammation in Mice

Overview
Publisher Informa Healthcare
Date 2016 Apr 22
PMID 27098091
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Pristimerin has been shown to possess antiinflammatory activity. However, its potential use for asthma induced by airway inflammation has not yet been studied. First, we established a ovalbumin (OVA)-induced allergic asthma mice model. BALB/c mice were immunized and challenged by OVA. Treatment with pristimerin caused a marked reduction in the levels of OVA-specific IgE, immune cells, and IL-4, IL-5, IL-13 secretion. Histological studies using H&E staining were used to study the alterations in lung tissue. These results were similar to those obtained with dexamethasone treatment. We then investigated which signal transduction mechanisms could be implicated in pristimerin activity by Western blot. The data showed that pristimerin could inhibit MAPKs and NF-κB inflammatory pathways.

Citing Articles

Immunomodulatory properties of triterpenes.

Renda G, Gokkaya I, Sohretoglu D Phytochem Rev. 2021; 21(2):537-563.

PMID: 34812259 PMC: 8600492. DOI: 10.1007/s11101-021-09785-x.


Cellular and Molecular Mechanisms of Pristimerin in Cancer Therapy: Recent Advances.

Chen R, Yang F, Zhang M, Sun Z, Zhang N Front Oncol. 2021; 11:671548.

PMID: 34026649 PMC: 8138054. DOI: 10.3389/fonc.2021.671548.


Pristimerin Suppresses RANKL-Induced Osteoclastogenesis and Ameliorates Ovariectomy-Induced Bone Loss.

Qi D, Liu H, Sun X, Luo D, Zhu M, Tao T Front Pharmacol. 2021; 11:621110.

PMID: 33628184 PMC: 7898668. DOI: 10.3389/fphar.2020.621110.


Pristimerin protects against doxorubicin-induced cardiotoxicity and fibrosis through modulation of Nrf2 and MAPK/NF-kB signaling pathways.

El-Agamy D, El-Harbi K, Khoshhal S, Ahmed N, Elkablawy M, Shaaban A Cancer Manag Res. 2018; 11:47-61.

PMID: 30588110 PMC: 6304079. DOI: 10.2147/CMAR.S186696.


Pristimerin as a Novel Hepatoprotective Agent Against Experimental Autoimmune Hepatitis.

El-Agamy D, Shaaban A, Almaramhy H, Elkablawy S, Elkablawy M Front Pharmacol. 2018; 9:292.

PMID: 29643811 PMC: 5883828. DOI: 10.3389/fphar.2018.00292.